EU Legal & Regulatory Update -- November 2012.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 1, p. 59, doi. 10.5912/jcb.596
- By:
- Publication type:
- Article
Works matching IS 14628732 AND DT 2013 AND VI 19 AND IP 1
Results: 9
1
2
Use of medicines for carved out indications in Europe -- Time for a change in approach?
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 1, p. 55, doi. 10.5912/jcb591
- By:
- Publication type:
- Article
3
China's heparin revisited: What went wrong and has anything changed?
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 1, p. 33, doi. 10.5912/jcb579
- By:
- Publication type:
- Article
4
A snapshot of the successful bioclusters around the world: Lessons for South African biotechnology.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 1, p. 40, doi. 10.5912/jcb544
- By:
- Publication type:
- Article
5
Improving IPO market still not an exit path.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 1, p. 53, doi. 10.5912/jcb593
- By:
- Publication type:
- Article
6
Biotechnology valuation and governance: Drug development and board of directors composition.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 1, p. 7, doi. 10.5912/jcb561
- By:
- Publication type:
- Article
7
NPV modelling for the selection of value-creating biosimilar development candidates.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 1, p. 24, doi. 10.5912/jcb578
- By:
- Publication type:
- Article
8
Fixing a broken drug development process.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 1, p. 5, doi. 10.5912/jcb588
- By:
- Publication type:
- Article
9
The other side of innovation.
- Published in:
- 2013
- By:
- Publication type:
- Opinion